Tango Therapeutics (TNGX) Cash & Equivalents (2020 - 2025)
Historic Cash & Equivalents for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $58.3 million.
- Tango Therapeutics' Cash & Equivalents rose 976.52% to $58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.3 million, marking a year-over-year increase of 976.52%. This contributed to the annual value of $69.5 million for FY2024, which is 39.82% down from last year.
- Per Tango Therapeutics' latest filing, its Cash & Equivalents stood at $58.3 million for Q3 2025, which was up 976.52% from $39.3 million recorded in Q2 2025.
- Tango Therapeutics' Cash & Equivalents' 5-year high stood at $207.3 million during Q3 2021, with a 5-year trough of $39.3 million in Q2 2025.
- In the last 5 years, Tango Therapeutics' Cash & Equivalents had a median value of $61.2 million in 2024 and averaged $78.6 million.
- As far as peak fluctuations go, Tango Therapeutics' Cash & Equivalents surged by 21268357.94% in 2021, and later tumbled by 5864.96% in 2022.
- Tango Therapeutics' Cash & Equivalents (Quarter) stood at $145.0 million in 2021, then crashed by 58.65% to $60.0 million in 2022, then grew by 16.41% to $69.8 million in 2023, then dropped by 0.4% to $69.5 million in 2024, then fell by 16.1% to $58.3 million in 2025.
- Its Cash & Equivalents stands at $58.3 million for Q3 2025, versus $39.3 million for Q2 2025 and $58.4 million for Q1 2025.